Search

everythinglearnresearchcommunity

for

Search:↓

New treatments for Frontal Fibrosing Alopecia show promise, especially finasteride and dutasteride, with most patients seeing improvement or stabilization.

A protein called sFRP4 from skin cells stops the development of pigment-producing cells in hair.

Reduced TRPS1 leads to increased STAT3 and SOX9 in hair follicles, affecting hair growth.

The paper suggests that a decrease in estrogen receptor activity may cause sexual dysfunction syndromes and proposes hormonal treatments.

Low levels of vitamin D and ferritin may increase the risk of female pattern hair loss.

Post-Finasteride Syndrome causes lasting sexual, mood, and metabolic issues, needing personalized treatment and better informed consent.

Spironolactone effectively treats female pattern hair loss with few side effects.

Topical finasteride may help treat facial hirsutism in women.

The review suggests younger men taking 1 mg finasteride report more side effects, including sexual, skin, metabolic, and psychological issues.

Female pattern hair loss and polycystic ovary syndrome are often linked.

FFA can be mistaken for rosacea, requiring specific treatment for accurate diagnosis and management.

Injectable platelet-rich fibrin improves hair growth and reduces hair loss in women.

Frontal Fibrosing Alopecia is a hair loss condition mainly affecting postmenopausal women, with unclear causes and various clinical patterns.

Feminizing hormone therapy increases hair counts and improves hair-related quality of life, while masculinizing therapy may reduce large terminal hairs.

Blocking 5α-reductase can reduce sleep deprivation-related behavioral issues in rats.

Female pattern hair loss involves hormonal factors, genetics, and may be linked to low ferritin levels.

Hesperidin protects rat testicles from finasteride damage and improves sperm health.

Spironolactone helps reduce hair growth in women with hirsutism but may cause menstrual irregularities.

Patients with PCOS rate their hirsutism higher than clinicians, and these self-ratings are more closely related to their quality of life and risk of depression.

Chronic GnRHa treatment can help manage endometrial hyperplasia and reduce ovarian androgen excess in PCO patients.

The document concludes that more research is needed to understand excessive hair growth in women with normal hormone levels and regular ovulation.

Combined finasteride and spironolactone therapy significantly improves quality of life in women with PCOS.

The type of previous hair restoration surgery might affect the success of a later one, with strip harvesting possibly leading to fewer damaged hair follicles.

Dihydrotestosterone has a reduced effect on muscle-building in people with testicular feminization syndrome, especially after their gonads are removed.

Hirsutism is excessive male-pattern hair growth in women, often treated cosmetically or with hormone therapy if contraception is also desired.

Fgf20 is important for the development and regulation of the cells that form the base of hair follicles.

Finasteride reduces sperm count and affects male reproductive function, while Epristeride does not.

Some treatments like intralesional steroids and 5α-reductase inhibitors are effective for frontal fibrosing alopecia, but more research is needed.

Deferasirox effectively reduces iron overload in ß-thalassemia patients but may cause some manageable side effects.